mono TRuC-T CD70 cell therapy / Adaptimmune - LARVOL DELTA

Adaptimmune Provides Q4 and Full Year 2024 Business Update (Adaptimmune Press Release) - "Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026...Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years."

FDA approval • FDA filing • Pricing • Oncology • Soft Tissue Sarcoma • Synovial Sarcoma

A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells (SITC 2021) - "In vivo, the anti-tumor activity of CD70-targeted TRuC-T cells was significantly improved by IL-15fu in multiple tumor models and was associated with enhanced intratumoral T-cell accumulation and a preferential expansion of CD8+ T cells. Conclusions The addition of the IL-15fu improved the phenotype, persistence, and anti-tumor activity of CD70-targeted TRuC-T cells, potentially increasing the likelihood of clinical benefit in patients with CD70 overexpressing solid and liquid cancers."

Clinical • IO biomarker • Hematological Malignancies • Oncology • Solid Tumor • CD70 • CD8 • IL15 • IL7